文献速递基础与转化研究临床试验与 GCP

人皮肤共生菌治疗特应性皮炎的开发及1期随机临床试验

Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.
PubMed 文献 · Nat Med · 2021-02-22

本研究开发了健康人皮肤分离的Staphylococcus hominis A9(ShA9)作为特应性皮炎(AD)的局部疗法。小鼠中ShA9可杀死金黄色葡萄球菌并抑制其毒素psmα表达。54名金黄色葡萄球菌阳性AD成人参与1期双盲随机试验,局部应用ShA9或赋形剂1周,达到安全性主要终点,ShA9组AD相关不良事件更少;湿疹严重度无显著差异,但金黄色葡萄球菌减少和ShA9 DNA增加达到次要终点;事后分析提示对ShA9直接杀灭的菌株感染者局部湿疹改善。

要点

  • ShA9局部应用安全性达到主要终点,AD相关不良事件更少。
  • ShA9可减少皮肤金黄色葡萄球菌并抑制psmα毒素表达。
  • 事后分析提示对ShA9敏感菌株感染者局部湿疹可能改善。

核心结论

  • 局部应用ShA9在AD患者中安全,并可能通过杀死金黄色葡萄球菌和抑制psmα表达产生获益。

研究设计与样本

  • 首次人体、1期、双盲、随机、为期1周的试验,在54名金黄色葡萄球菌阳性AD成人前臂皮肤局部应用ShA9或赋形剂(NCT03151148)。

主要发现

  • ShA9在小鼠皮肤上杀死金黄色葡萄球菌并抑制促进炎症的psmα表达。
  • 试验达到安全性主要终点,ShA9组AD相关不良事件更少。
  • 全部参与者中湿疹严重度无显著差异,但金黄色葡萄球菌减少和ShA9 DNA增加达到次要终点。
  • 部分金黄色葡萄球菌菌株未被ShA9直接杀死,但所有菌株的psmα mRNA表达均被抑制。
  • 事后分析提示,对ShA9直接杀死菌株的参与者局部湿疹严重度有改善。

临床怎么用

  • ShA9作为局部细菌疗法在AD中显示安全性和潜在获益,支持进一步临床开发。

局限性

  • 湿疹严重度改善仅来自事后分析,需更大样本验证。
  • 部分金黄色葡萄球菌菌株未被ShA9直接杀死。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Staphylococcus aureus colonizes patients with atopic dermatitis (AD) and exacerbates disease by promoting inflammation. The present study investigated the safety and mechanisms of action of Staphylococcus hominis A9 (ShA9), a bacterium isolated from healthy human skin, as a topical therapy for AD. ShA9 killed S. aureus on the skin of mice and inhibited expression of a toxin from S. aureus (psmα) that promotes inflammation. A first-in-human, phase 1, double-blinded, randomized 1-week trial of topical ShA9 or vehicle on the forearm skin of 54 adults with S. aureus-positive AD (NCT03151148) met its primary endpoint of safety, and participants receiving ShA9 had fewer adverse events associated with AD. Eczema severity was not significantly different when evaluated in all participants treated with ShA9 but a significant decrease in S. aureus and increased ShA9 DNA were seen and met secondary endpoints. Some S. aureus strains on participants were not directly killed by ShA9, but expression of mRNA for psmα was inhibited in all strains. Improvement in local eczema severity was suggested by post-hoc analysis of participants with S. aureus directly killed by ShA9. These observations demonstrate the safety and potential benefits of bacteriotherapy for AD.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Nakatsuji T, Hata TR, Tong Y, et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat Med. 2021. PMID: 33619370. doi:10.1038/s41591-021-01256-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。